


OVERVIEW

- Focus on repurposing drugs for rare & infectious diseases
- Advancing clinical development of Bucillamine for infectious diseases, including COVID-19 (FDA Phase 3)
- Developing Psilocybin, MDMA and Cannabidiol therapeutics
- Robust patent portfolio ([15 patents and patent applications](#))
- Awarded FDA Orphan Drug Status for CBD in the treatment of Autoimmune Hepatitis
- Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)

PRODUCT PIPELINE

Product	Indication	Stage of Development	Regulatory Status
Bucillamine	Infectious Diseases COVID-19	Phase 3 (COVID-19)	FDA approved for Phase 3
Psilocybin	Substance Use Disorder Methamphetamine	Phase 1/2	CTA with University of Wisconsin
Psilocybin	Neurological TBI (Concussion), Stroke	Phase 1/2	CTA with University of Wisconsin
Psilocybin (Oral Thin Film)	Mental Health Depression, Anxiety	IND-enabling	Target FDA Approval
Cannabidiol CBD	Liver Diseases Autoimmune Hepatitis	Filing IND	Plan for Phase 2

STRATEGIC PARTNERS



EXPECTED MILESTONES 1H-2023

- ▶ Finalize FDA pathway of Phase 3 study and potential unblinding of data
- ▶ Schedule of DSMB meeting for COVID-19 Phase 3 study primary endpoint
- ▶ Phase 1/2 study - Psilocybin in Methamphetamine Disorder at University of Wisconsin
- ▶ Manufacturing Psilocybin oral thin film strip for FDA IND
- ▶ Manufacturing of MDMA patch for research purposes

TEAM

Management

Michael Frank, Chairman & CEO
Carmelo Marrelli, CFO
Derrick Welch, COO, Psilocin Pharma

Scientific and Clinical

Dr. Kelly McKee, CSO
Dr. Arshi Kizilbash, M.D.
Dr. Osnesmo Mpanju, Regulatory Affairs
Dr. John Fahy, MD, Clinical and Scientific Advisor

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

CONTACT INFORMATION

Revive Therapeutics Ltd.
82 Richmond Street East
Toronto, ON M5C 1P1

Tel: 1-888-901-0036
E-mail: info@revivether.com
Website: revivether.com

STOCK INFORMATION

Ticker:	CSE: RVV, OTCQB: RVVTF, FRANKFURT: 31R
Share Price:	\$0.06 (March 22, 2023)
52-week High / Low:	CAD \$0.49 / \$0.04
Shares Outstanding:	356,237,674
Market Cap:	CAD ~ 22,000,000

